Nonnucleotide Reverse-Transcriptase Inhibitors and Treatment Interruption

被引：2
作者：
DiNubile, Mark J. [1 ]
机构：
[1] Merck Res Labs, West Point, PA USA
来源：
CLINICAL INFECTIOUS DISEASES | 2008年 / 47卷 / 12期
关键词：
D O I：
10.1086/593361
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：1602 / 1602
页数：1
相关论文
共 8 条
  • [1] Superiority of protease inhibitors over nonnucleoside reverse-transcriptase inhibitors when highly active antiretroviral therapy is resumed after treatment interruption
    Barreiro, P
    de Mendoza, C
    González-Lahoz, J
    Soriano, V
    [J]. CLINICAL INFECTIOUS DISEASES, 2005, 41 (06) : 897 - 900
  • [2] Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children
    Cressey, Tim R.
    Green, Hannah
    Khoo, Saye
    Treluyer, Jean-Marc
    Compagnucci, Alexandra
    Saidi, Yacine
    Lallemant, Marc
    Gibb, Diana M.
    Burger, David M.
    Aboulker, J-P
    Babiker, A.
    Blanche, S.
    Bohlin, A. -B.
    Butler, K.
    Castelli-Gattinara, G.
    Clayden, P.
    Compagnucci, A.
    Darbyshire, J. H.
    Debre, M.
    de Groot, R.
    della Negra, M.
    Duicelescu, D.
    Giaquinto, C.
    Gibb, D. M.
    Grosch-Worner, I.
    Kind, C.
    Lallemant, M.
    Levy, J.
    Lyall, H.
    Marczynska, M.
    Mellado Pena, M. J.
    Nadal, D.
    Niehues, T.
    Peckham, C.
    Ramos Amador, J. T.
    Rosado, L.
    Rudin, C.
    Scherpbier, H. J.
    Sharland, M.
    Stevanovic, M.
    Tovo, P. A.
    Tudor-Williams, G.
    Valerius, N.
    Walker, A. S.
    Wintergerst, U.
    Harper, L.
    Klein, N.
    Mofenson, L.
    Moye, J.
    Jacqz-Aigrain, E.
    [J]. CLINICAL INFECTIOUS DISEASES, 2008, 46 (10) : 1601 - 1608
  • [3] British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006)
    Gazzard, B.
    [J]. HIV MEDICINE, 2006, 7 (08) : 487 - 503
  • [4] Treatment for adult HIV infection - 2006 recommendations of the International AIDS Society-USA panel
    Hammer, Scott M.
    Saag, Michael S.
    Schechter, Mauro
    Montaner, Julio S. G.
    Schooley, Robert T.
    Jacobsen, Donna M.
    Thompson, Melanie A.
    Carpenter, Charles C. J.
    Fischl, Margaret A.
    Gazzard, Brian G.
    Gatell, Jose M.
    Hirsch, Martin S.
    Katzenstein, David A.
    Richman, Douglas D.
    Vella, Stefano
    Yeni, Patrick G.
    Volberding, Paul A.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (07): : 827 - 843
  • [5] Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy
    Hare, C. Bradley
    Mellors, John
    Krambrink, Amy
    Su, Zhaohui
    Skiest, Daniel
    Margolis, David M.
    Patel, Sheran S.
    Barnas, Douglas
    Frenkel, Lisa
    Coombs, Robert W.
    Aweeka, Francesca
    Morse, Gene D.
    Haas, David W.
    Boltz, Valerie
    Palmer, Sarah
    Coffin, John
    Havlir, Diane V.
    [J]. CLINICAL INFECTIOUS DISEASES, 2008, 47 (03) : 421 - 424
  • [6] Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: An adult AIDS clinical trials group study
    Ribaudo, HJ
    Haas, DW
    Tierney, C
    Kim, RB
    Wilkinson, GR
    Gulick, RM
    Clifford, DB
    Marzolini, C
    Fletcher, CV
    Tashima, KT
    Kuritzkes, DR
    Acosta, EP
    [J]. CLINICAL INFECTIOUS DISEASES, 2006, 42 (03) : 401 - 407
  • [7] U. S. Department of Health and Human Services, 2012, GUID US ANT AG HIV 1
  • [8] van Loon Luc J. C., 2007, Immunology Endocrine & Metabolic Agents in Medicinal Chemistry, V7, P39
1